Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
Phase 3 Completed
394 enrolled 11 charts
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
Phase 3 Completed
3,436 enrolled
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 3 Completed
139 enrolled 10 charts
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
Phase 2 Completed
73 enrolled 13 charts
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
Phase 2 Completed
19 enrolled 6 charts
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Phase 3 Completed
60 enrolled
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
Phase 2 Completed
43 enrolled 11 charts
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
Phase 2 Completed
226 enrolled 8 charts
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
Phase 3 Completed
2,000 enrolled
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
Phase 3 Completed
1,000 enrolled
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
Phase 3 Completed
1,000 enrolled
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
Phase 3 Completed
600 enrolled
Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer
Phase 3 Completed
642 enrolled
Chemotherapy Plus Surgery in Treating Women With Breast Cancer
Phase 3 Completed
450 enrolled
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
Phase 3 Completed
4,400 enrolled
Tamoxifen in Treating Patients With Primary Liver Cancer
Phase 3 Completed
300 enrolled
Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
Phase 3 Completed
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
Phase 2 Completed
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
Phase 2 Completed
200 enrolled
Combination Chemotherapy in Treating Women With Breast Cancer
Phase 3 Completed
446 enrolled
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
Phase 2 Completed
30 enrolled 12 charts
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
Phase 3 Completed
1,500 enrolled
Tamoxifen Pharmacogenetics and Clinical Effects
Completed
297 enrolled
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
Phase 1 Completed
24 enrolled